KMT2B
KMT2B (Histone-lysine N-methyltransferase 2B) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Hepatocellular carcinoma, Vulvar cancer, Melanoma and 1 more.
Overview
Histone methyltransferase that catalyses methyl group transfer from S-adenosyl-L-methionine to the epsilon-amino group of 'Lys-4' of histone H3 (H3K4) via a non-processive mechanism. Part of chromatin remodeling machinery predominantly forms H3K4me1 and H3K4me2 methylation marks at active chromatin sites where transcription and DNA repair take place. Likely plays a redundant role with KMT2C in enriching H3K4me1 marks on primed and active enhancer elements.
CIViC holds 2 clinical evidence items and 0 assertions across 1 variant, naming Immune Checkpoint Inhibitor. IntOGen calls it a driver in 2 cohorts (0 activating, 2 loss-of-function), covering Hepatocellular Carcinoma, Vulva/Vagina.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · KMT2B (Histone-lysine N-methyltransferase 2B) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Hepatocellular carcinoma, Vulvar cancer, Melanoma and 1 more.
- 1 · What it is
KMT2B (Histone-lysine N-methyltransferase 2B) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Hepatocellular carcinoma, Vulvar cancer, Melanoma and 1 more.
- 2 · What goes wrong in cancer
Histone methyltransferase that catalyses methyl group transfer from S-adenosyl-L-methionine to the epsilon-amino group of 'Lys-4' of histone H3 (H3K4) via a non-processive mechanism.
- 3 · How drugs use it
No product in this corpus aims at KMT2B yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
External identifiers
Sources: HGNC HGNC:15840 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q9UMN6 (protein name, function text, keywords and locations (REST API)); CIViC gene KMT2B (2 evidence items, 0 assertions, 1 variants; diseases: Melanoma, Lung Non-small Cell Carcinoma (GraphQL API, CC0)); IntOGen KMT2B (driver in 2 cohorts (Act 0, LoF 2); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Histone methyltransferase that catalyses methyl group transfer from S-adenosyl-L-methionine to the epsilon-amino group of 'Lys-4' of histone H3 (H3K4) via a non-processive mechanism. Part of chromatin remodeling machinery predominantly forms H3K4me1 and H3K4me2 methylation marks at active chromatin sites where transcription and DNA repair take place. Likely plays a redundant role with KMT2C in enriching H3K4me1 marks on primed and active enhancer elements. Plays a central role in beta-globin locus transcription regulation by being recruited by NFE2. Plays an important role in controlling bulk H3K4me during oocyte growth and preimplantation development. Required during the transcriptionally active period of oocyte growth for the establishment and/or maintenance of bulk H3K4 trimethylation (H3K4me3), global transcriptional silencing that preceeds resumption of meiosis, oocyte survival and normal zygotic genome activation. Location: Nucleus (UniProt). Locus 19q13.12 (HGNC).
- Hepatocellular carcinoma: IntOGen driver in 1 cohort (HCC)
- Vulvar cancer: IntOGen driver in 1 cohort (VULVA)
- Melanoma: CIViC evidence names this disease
- Non-small-cell lung cancer: CIViC evidence names this disease
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 1 therapies; IntOGen calls it a loss-of-function (LoF) driver in 2 cohorts; CIViC holds 2 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"KMT2B" OR ABSTRACT:"KMT2B" OR TITLE:"lysine methyltransferase 2B" OR ABSTRACT:"lysine methyltransferase 2B" OR TITLE:"Histone-lysine N-methyltransferase 2B" OR ABSTRACT:"Histone-lysine N-methyltransferase 2B" OR TITLE:"KIAA0304" OR ABSTRACT:"KIAA0304" OR TITLE:"MLL2" OR ABSTRACT:"MLL2" OR TITLE:"TRX2" OR ABSTRACT:"TRX2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about KMT2B, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetFAT2
Shares Vulvar cancer, IntOGen.
- TargetZFHX3
Shares Vulvar cancer, Hepatocellular carcinoma, IntOGen.
- TargetMAML2
Shares Vulvar cancer, IntOGen, Non-small-cell lung cancer.
- TargetBCL11B
Shares Vulvar cancer, IntOGen.
- TechnologyCompression, decongestive therapy and exercise for lymphoedema
Shares Vulvar cancer, Melanoma.
- TechnologyGamma probes, handheld gamma cameras and dose calibrators
Shares Vulvar cancer, Melanoma.